Log In
Monday 24th June 2019

50% rise in rejected cancer drugs in two years

29th August 2012

A report by the Rarer Cancers Foundation has found the National Institute for Health and Clinical Excellence (NICE) turned down 11 out of 19 new cancer treatments in 2011/12.


The charity said the amount of cancer treatments rejected by NICE had increased by 50% in two years.

The report showed that in 2009/10 seven treatments were turned down out of 15 put forward.

The Daily Mail reported that the charity showed there was a "stark postcode lottery" and that many people were not being given funding although in 2011, £89 million of the £200 million the government earmarked to pay for cancer treatment was not spent.

Andrew Wilson, the charity's chief executive, said: "It is concerning that there are widespread variations in the treatments which are routinely available, increasing  anxiety for patients and resulting  in unnecessary bureaucracy."

"At a time when the Cancer Drugs Fund is underspent, it is unacceptable that patients are still being turned down for the drugs their doctors think could help them."

A NICE spokesman said: "If a drug is clinically and cost-effective then we will recommend it for use on the NHS...but if there isn’t sufficient evidence to show that a drug provides benefits over and above currently available medicines, or if the price the NHS is being asked to pay is too high to justify its benefits, then we cannot recommend it."


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2019